GF
VRTX icon

Gabelli Funds’s Vertex Pharmaceuticals VRTX Stock Holding History

Gabelli Funds’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92M Sell
7,891
-29
-0.4% -$12.9K 0.03% 597
2026
Q1 		$3.54M Sell
7,920
-64
-0.8% -$29.8K 0.02% 591
2025
Q4 		$3.62M Sell
7,984
-7,018
-47% -$3.02M 0.02% 577
2025
Q3 		$5.88M Sell
15,002
-1,327
-8% -$555K 0.04% 450
2025
Q2 		$7.27M Sell
16,329
-21
-0.1% -$9.68K 0.05% 389
2025
Q1 		$7.93M Sell
16,350
-1,324
-7% -$617K 0.06% 343
2024
Q4 		$7.12M Buy
17,674
+275
+2% +$127K 0.05% 362
2024
Q3 		$8.09M Sell
17,399
-4,693
-21% -$2.25M 0.06% 345
2024
Q2 		$10.4M Sell
22,092
-217
-1% -$94.2K 0.08% 303
2024
Q1 		$9.33M Sell
22,309
-480
-2% -$203K 0.07% 321
2023
Q4 		$9.27M Buy
22,789
+105
+0.5% +$38.8K 0.07% 310
2023
Q3 		$7.89M Sell
22,684
-465
-2% -$163K 0.06% 340
2023
Q2 		$8.15M Sell
23,149
-1,492
-6% -$503K 0.06% 346
2023
Q1 		$7.76M Buy
24,641
+1,477
+6% +$443K 0.06% 364
2022
Q4 		$6.69M Buy
23,164
+1,158
+5% +$353K 0.05% 391
2022
Q3 		$6.37M Sell
22,006
-4,095
-16% -$1.18M 0.05% 396
2022
Q2 		$7.36M Sell
26,101
-11,861
-31% -$3.17M 0.06% 383
2022
Q1 		$9.91M Buy
37,962
+6,666
+21% +$1.58M 0.07% 347
2021
Q4 		$6.87M Buy
31,296
+6,000
+24% +$1.17M 0.04% 433
2021
Q3 		$4.59M Buy
25,296
+15,421
+156% +$3.01M 0.03% 528
2021
Q2 		$1.99M Buy
+9,875
New +$2.07M 0.01% 755

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Gabelli Funds's VRTX Position: Q2 2026 in Review

Gabelli Funds reduced its Vertex Pharmaceuticals (VRTX) stake by 0.37% in Q2 2026, selling an estimated $12.9K and leaving 7,891 shares worth $3.92M. The position accounts for 0.03% of the portfolio, ranked #597.

Gabelli Funds first reported a position in VRTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $10.4M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Gabelli Funds held 7,891 shares of Vertex Pharmaceuticals worth $3.92M as of Q2 2026.
  • Gabelli Funds sold 29 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
  • Vertex Pharmaceuticals made up 0.03% of Gabelli Funds's portfolio in Q2 2026, its #597 holding.
  • Gabelli Funds first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Gabelli Funds's Vertex Pharmaceuticals position peaked at $10.4M in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.